Micronized Purified Flavonoid Fraction and the Treatment of Chronic Venous Insufficiency: Microcirculatory Mechanisms

Smith, Philip

doi:10.1111/j.1549-8719.2000.tb00149.x

Cited by 13 publications

(6 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this regard, hesperidin was found to significantly prevent endothelial damage and leucocytes adhesion in animal models of ischemia reperfusion. Concomitantly, an increase of NO bioavailability and a reduction of inflammatory molecules which contribute to ameliorate edema and other symptoms of venous diseases have been reported [ 203 ].…”

Section: Polyphenols and The No Signalingmentioning

confidence: 99%

Targeting Nitric Oxide with Natural Derived Compounds as a Therapeutic Strategy in Vascular Diseases

Forte

Conti

Damato

et al. 2016

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Within the family of endogenous gasotransmitters, nitric oxide (NO) is the smallest gaseous intercellular messenger involved in the modulation of several processes, such as blood flow and platelet aggregation control, essential to maintain vascular homeostasis. NO is produced by nitric oxide synthases (NOS) and its effects are mediated by cGMP-dependent or cGMP-independent mechanisms. Growing evidence suggests a crosstalk between the NO signaling and the occurrence of oxidative stress in the onset and progression of vascular diseases, such as hypertension, heart failure, ischemia, and stroke. For these reasons, NO is considered as an emerging molecular target for developing therapeutic strategies for cardio- and cerebrovascular pathologies. Several natural derived compounds, such as polyphenols, are now proposed as modulators of NO-mediated pathways. The aim of this review is to highlight the experimental evidence on the involvement of nitric oxide in vascular homeostasis focusing on the therapeutic potential of targeting NO with some natural compounds in patients with vascular diseases.

show abstract

Section: Polyphenols and The No Signalingmentioning

confidence: 99%

Targeting Nitric Oxide with Natural Derived Compounds as a Therapeutic Strategy in Vascular Diseases

Forte

Conti

Damato

et al. 2016

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

show abstract

“…Thus, Daflon V R protects the microcirculation which decreases capillary damage. [14][15][16] The current study tried to evaluate the efficacy and safety of Daflon V R in the treatment of recurrent idiopathic epistaxis. The rationale for its use was based on the previously proposed underlying venous disorder for epistaxis with the well-known beneficial effect for Daflon V R in managing such problem.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Daflon® in the Treatment of Idiopathic Epistaxis

Attia

2018

Am J Rhinol�Allergy

View full text Add to dashboard Cite

Background Epistaxis is a very common ENT emergency with the idiopathic variety being the commonest type. Daflon® is a mixture of flavonoids with beneficial vascular effects that may help in the treatment of epistaxis. Objective To assess the efficacy and safety of Daflon® in the treatment of idiopathic epistaxis. Methods This is an open-label randomized clinical trial conducted on patients with idiopathic epistaxis comparing 1 group receiving Daflon® for 1 month and a second group receiving Daflon® for 3 months with a control group receiving nothing. The groups were evaluated regarding the number of visits to an emergency room and the number of patients needing cautery as indicators for the control of epistaxis. Also, the severity of epistaxis was assessed using epistaxis severity score (ESS) before and after treatment. We followed the patients for 1 year to determine the long-term effect of both drug protocols. Results The study included 450 patients distributed equally among the 3 study groups. The administration of Daflon® whether for 1 month or 3 months resulted in a significant improvement in our indicators for control of epistaxis including the number of patients visiting an emergency room and those needing cauterization after the failure of light nasal packing when compared with control group. Also, the severity of epistaxis as defined by the ESS was significantly less at the end of each treatment period and at 1-year follow-up when compared with the pretreatment severity. However, the use of Daflon® for 3 months was associated with a significantly more epistaxis control at 1-year follow-up when compared with the 1-month administration. Conclusion Daflon® is a very effective and safe method for controlling idiopathic epistaxis. However, the daily use of Daflon® for 3 months has a more significant long-term beneficial effect than 1 month of use.

show abstract

“…9–11 The precise mechanisms of action of venoactive drugs remain incompletely understood, but they are thought to improve venous tone and counter some of the microcirculatory responses by decreasing white cell activation, reducing capillary fragility and permeability, and inhibiting inflammatory pathways. 15–17…”

Section: Classification Of Medication Used In Venous Diseasementioning

confidence: 99%

“…MPFF has been evaluated in basic scientific in addition to clinical studies. Potential mechanisms of action are thought to be similar to other flavones and flavonoid derivatives 15,16 and include:…”

Section: Pharmacotherapy For Chronic Venous Disease (C4)mentioning

confidence: 99%